JPWO2020028222A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020028222A5 JPWO2020028222A5 JP2021505236A JP2021505236A JPWO2020028222A5 JP WO2020028222 A5 JPWO2020028222 A5 JP WO2020028222A5 JP 2021505236 A JP2021505236 A JP 2021505236A JP 2021505236 A JP2021505236 A JP 2021505236A JP WO2020028222 A5 JPWO2020028222 A5 JP WO2020028222A5
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- alkyl
- substituted
- groups
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003118 aryl group Chemical group 0.000 claims description 170
- 125000000217 alkyl group Chemical group 0.000 claims description 149
- 229910052739 hydrogen Inorganic materials 0.000 claims description 82
- 239000001257 hydrogen Substances 0.000 claims description 82
- 125000003342 alkenyl group Chemical group 0.000 claims description 80
- 125000000304 alkynyl group Chemical group 0.000 claims description 75
- 150000002431 hydrogen Chemical class 0.000 claims description 75
- 125000001072 heteroaryl group Chemical group 0.000 claims description 74
- 125000003545 alkoxy group Chemical group 0.000 claims description 46
- 150000001875 compounds Chemical class 0.000 claims description 38
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 36
- -1 hydroxy, nitro, aminosulfonyl Chemical group 0.000 claims description 36
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 24
- 238000006467 substitution reaction Methods 0.000 claims description 24
- 125000001475 halogen functional group Chemical group 0.000 claims description 22
- 125000002252 acyl group Chemical group 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 12
- 125000000732 arylene group Chemical group 0.000 claims description 11
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 208000012902 Nervous system disease Diseases 0.000 claims description 6
- 206010015037 epilepsy Diseases 0.000 claims description 5
- 208000012268 mitochondrial disease Diseases 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 208000020925 Bipolar disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 208000025966 Neurological disease Diseases 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010003694 Atrophy Diseases 0.000 claims description 2
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 claims description 2
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 206010026749 Mania Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 230000037444 atrophy Effects 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 201000002697 mitochondrial DNA depletion syndrome Diseases 0.000 claims description 2
- 230000008811 mitochondrial respiratory chain Effects 0.000 claims description 2
- 230000000926 neurological effect Effects 0.000 claims description 2
- 210000001328 optic nerve Anatomy 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 27
- 201000010099 disease Diseases 0.000 description 2
- FRASJONUBLZVQX-UHFFFAOYSA-N 1,4-naphthoquinone Chemical compound C1=CC=C2C(=O)C=CC(=O)C2=C1 FRASJONUBLZVQX-UHFFFAOYSA-N 0.000 description 1
- JLOBMWCZCWALTQ-UHFFFAOYSA-N 2-(3-methylbutylamino)naphthalene-1,4-dione Chemical compound CC(CCNC=1C(C2=CC=CC=C2C(C=1)=O)=O)C JLOBMWCZCWALTQ-UHFFFAOYSA-N 0.000 description 1
- BEBJBQQKJDMSRW-UHFFFAOYSA-N 2-(3-phenylprop-2-ynylamino)naphthalene-1,4-dione Chemical compound C1(=CC=CC=C1)C#CCNC=1C(C2=CC=CC=C2C(C=1)=O)=O BEBJBQQKJDMSRW-UHFFFAOYSA-N 0.000 description 1
- BATAHUJPPGPXIN-UHFFFAOYSA-N 2-butoxynaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(OCCCC)=CC(=O)C2=C1 BATAHUJPPGPXIN-UHFFFAOYSA-N 0.000 description 1
- WKPLBYROQOFCMV-UHFFFAOYSA-N 2-phenylmethoxynaphthalene-1,4-dione Chemical compound O=C1C2=CC=CC=C2C(=O)C=C1OCC1=CC=CC=C1 WKPLBYROQOFCMV-UHFFFAOYSA-N 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862711575P | 2018-07-29 | 2018-07-29 | |
| US62/711,575 | 2018-07-29 | ||
| PCT/US2019/043868 WO2020028222A1 (en) | 2018-07-29 | 2019-07-29 | Compounds for the treatment of neurological or mitochondrial diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021533115A JP2021533115A (ja) | 2021-12-02 |
| JP2021533115A5 JP2021533115A5 (https=) | 2022-08-05 |
| JPWO2020028222A5 true JPWO2020028222A5 (https=) | 2022-08-05 |
Family
ID=69232050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021505236A Pending JP2021533115A (ja) | 2018-07-29 | 2019-07-29 | 神経疾患またはミトコンドリア疾患の処置のための化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11771685B2 (https=) |
| EP (1) | EP3829560A4 (https=) |
| JP (1) | JP2021533115A (https=) |
| KR (1) | KR20210071949A (https=) |
| CN (1) | CN112770735A (https=) |
| WO (1) | WO2020028222A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4122458A4 (en) * | 2020-03-17 | 2024-05-01 | Penta Labor Inc. | AGENT ATTENUATING MITOCHONDRIAL DYSFUNCTION |
| IT202100006065A1 (it) * | 2021-03-15 | 2022-09-15 | Univ Degli Studi Padova | Composto per l’uso nel metodo di trattamento delle malattie mitocondriali da disfunzione dei complessi i, ii, iii della catena respiratoria |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4195998A (en) | 1974-04-15 | 1980-04-01 | Eastman Kodak Company | CO(III) Complex containing radiation sensitive element with diazo recording layer |
| US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
| US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| WO1993000077A1 (en) | 1991-06-21 | 1993-01-07 | University Of Cincinnati | Orally administrable therapeutic proteins and method of making |
| US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
| ES2105262T3 (es) | 1992-05-18 | 1997-10-16 | Minnesota Mining & Mfg | Dispositivo de suministro de farmaco a traves de las mucosas. |
| US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| FR2742151B1 (fr) * | 1995-12-12 | 1998-03-06 | Innothera Lab Sa | Utilisation de derives de bicycles mono ou dicetoniques, nouveaux composes obtenus et leur application en therapeutique |
| US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| WO2005053609A2 (en) * | 2003-11-26 | 2005-06-16 | Guilford Pharmaceuticals Inc. | Methods of nad+-dependent deacetylase inhibitors |
| GB0816269D0 (en) * | 2008-09-05 | 2008-10-15 | Univ Ramot | Naphthoquinone derivatives useful for prevention of amyloid deposits and treatment of alzheimers disease |
| CN101712648B (zh) | 2009-11-23 | 2011-11-09 | 南京大学 | 氮杂蒽醌的合成方法 |
| EA201300215A1 (ru) | 2010-08-06 | 2013-07-30 | Эдисон Фармасьютикалз, Инк. | Лечение митохондриальных болезней нафтохинонами |
| EP2601168A4 (en) * | 2010-08-06 | 2013-12-04 | Ampere Life Sciences Inc | TREATMENT OF MITOCHONDRIAL DISEASES BY VITAMIN K |
| WO2012166862A1 (en) * | 2011-06-01 | 2012-12-06 | Wisconsin Alumni Research Foundation | Compositions and methods for treating alzheimer's disease |
| CN102321084B (zh) | 2011-10-13 | 2013-03-13 | 南京大学 | 苯并[c]吡啶并[4,3,2-mn]吖啶-8-酮的合成方法 |
| KR20140030786A (ko) | 2012-09-03 | 2014-03-12 | 희성소재 (주) | 신규한 화합물 및 이를 포함하는 유기전계발광소자 |
| WO2014074976A1 (en) | 2012-11-09 | 2014-05-15 | Musc Foundation For Research Development | Compositions and methods for treating neurological diseases or injury |
| US20150166476A1 (en) * | 2013-12-17 | 2015-06-18 | Yi-Cheng Chen | Methods for treating neurodegenerative diseases associated with aggregation of amyloid-beta |
| CN104761568B (zh) * | 2014-01-03 | 2017-10-10 | 中国科学院上海药物研究所 | 一类四环萘并噁唑衍生物及其制备方法 |
| EP3191087A1 (en) * | 2014-09-12 | 2017-07-19 | Pellficure Pharmaceuticals, Inc. | Compositions and methods for treatment of prostate carcinoma |
| CA2993809C (en) * | 2015-07-30 | 2023-09-05 | Taipei Medical University | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system |
-
2019
- 2019-07-29 WO PCT/US2019/043868 patent/WO2020028222A1/en not_active Ceased
- 2019-07-29 KR KR1020217006237A patent/KR20210071949A/ko not_active Withdrawn
- 2019-07-29 JP JP2021505236A patent/JP2021533115A/ja active Pending
- 2019-07-29 CN CN201980063585.2A patent/CN112770735A/zh active Pending
- 2019-07-29 EP EP19845102.3A patent/EP3829560A4/en active Pending
- 2019-07-29 US US17/264,714 patent/US11771685B2/en active Active
-
2023
- 2023-09-29 US US18/478,261 patent/US20240041849A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1091601C (zh) | 用苯酚取代的二磷酸酯作抗肿瘤剂 | |
| JP2020515610A5 (https=) | ||
| RU2009102278A (ru) | Модуляторы рецептора s1p для лечения рассеянного склероза | |
| JP2021524439A5 (https=) | ||
| JP6077265B2 (ja) | 自己免疫性疾患の処置剤 | |
| CN1652757A (zh) | Edg受体结合剂在癌症中的应用 | |
| CA2206794A1 (fr) | Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament | |
| JP2011509309A5 (https=) | ||
| JP2009526831A5 (https=) | ||
| JP2021533115A5 (https=) | ||
| JPWO2020106642A5 (https=) | ||
| JPWO2020028222A5 (https=) | ||
| CN1250215C (zh) | 用于预防或治疗双相性精神障碍的氨基甲酸酯化合物 | |
| JP2022502374A (ja) | 睡眠時無呼吸の治療のためのα２‐アドレナリン受容体サブタイプＣ （ＡＬＰＨＡ‐２Ｃ）拮抗薬 | |
| RU2019120431A (ru) | Производные триазинтриона и их использование в качестве модуляторов нейротрофиновых рецепторов и рецепторов тирозинкиназ | |
| JPWO2020234274A5 (https=) | ||
| JPWO2020234276A5 (https=) | ||
| EA202191075A1 (ru) | Соединения для применения в качестве терапевтически активных веществ при лечении и/или предотвращении нейроретинальных заболеваний | |
| KR20070022084A (ko) | 베타 효능제의 흡입용 에어로졸 제형 | |
| JPWO2019222269A5 (https=) | ||
| AU2020103878A4 (en) | Compounds and methods for treating influenza | |
| US20140242119A1 (en) | Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies | |
| US20250074899A1 (en) | A2-adrenoceptor subtype c antagonists for the treatment of sleep apnea | |
| HK40115453A (zh) | 用於治疗睡眠呼吸暂停的α2-肾上腺素受体亚型C拮抗剂 | |
| WO2018002873A1 (en) | Use of bgp15 to stimulate mitochondrial fusion |